AbbVie (ABBV) Equity Average (2013 - 2026)
AbbVie (ABBV) reported Equity Average of -$5.0 billion for Q1 2026, down 305.68% year-over-year from $2.4 billion in Q1 2025, and down 67.9% on a QoQ basis from -$3.0 billion in Q4 2025.
AbbVie (ABBV) has 14 years of Equity Average data on file, last reported at -$5.0 billion in Q1 2026.
- Quarterly Equity Average fell 305.68% year-over-year to -$5.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 billion (down 305.68% YoY) and the FY2025 annual result came in at $47.0 million, down 99.32% from the prior year.
- Equity Average declined to -$5.0 billion in Q1 2026 per ABBV's latest filing, from -$3.0 billion in the prior quarter.
- Across five years, Equity Average topped out at $16.7 billion in Q4 2022 and bottomed at -$5.0 billion in Q1 2026.
- The 5-year median for Equity Average is $9.2 billion (2024), against an average of $8.1 billion.
- The widest annual swing landed in 2022, when Equity Average increased 18.34%; it then tumbled 305.68% in 2026.
- Tracing ABBV's Equity Average over 5 years: stood at $16.7 billion in 2022, then slumped by 32.38% to $11.3 billion in 2023, then plunged by 58.12% to $4.7 billion in 2024, then sank by 162.66% to -$3.0 billion in 2025, then tumbled by 67.9% to -$5.0 billion in 2026.
- Per Business Quant, the three latest ABBV Equity Average figures stand at -$5.0 billion (Q1 2026), -$3.0 billion (Q4 2025), and -$1.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 19.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.96 Bn |
| Dec 31, 2025 | -2.96 Bn |
| Sep 30, 2025 | -1.39 Bn |
| Jun 30, 2025 | 662.00 Mn |
| Mar 31, 2025 | 2.41 Bn |
| Dec 31, 2024 | 4.72 Bn |
| Sep 30, 2024 | 6.45 Bn |
| Jun 30, 2024 | 7.43 Bn |
| Mar 31, 2024 | 9.22 Bn |
| Dec 31, 2023 | 11.26 Bn |
| Sep 30, 2023 | 12.51 Bn |
| Jun 30, 2023 | 13.10 Bn |
| Mar 31, 2023 | 15.30 Bn |
| Dec 31, 2022 | 16.66 Bn |
| Sep 30, 2022 | 15.36 Bn |
| Jun 30, 2022 | 15.50 Bn |
| Mar 31, 2022 | 15.88 Bn |
| Dec 31, 2021 | 14.51 Bn |
| Sep 30, 2021 | 13.09 Bn |
| Jun 30, 2021 | 13.16 Bn |
| Mar 31, 2021 | 13.42 Bn |
| Dec 31, 2020 | 14.19 Bn |
| Sep 30, 2020 | 15.01 Bn |
| Jun 30, 2020 | 3.66 Bn |
| Mar 31, 2020 | -7.79 Bn |
| Dec 31, 2019 | -8.20 Bn |
| Sep 30, 2019 | -8.40 Bn |
| Jun 30, 2019 | -8.20 Bn |
| Mar 31, 2019 | -8.14 Bn |
| Dec 31, 2018 | -5.68 Bn |
| Sep 30, 2018 | -3.15 Bn |
| Jun 30, 2018 | 89.00 Mn |
| Mar 31, 2018 | 4.33 Bn |
| Dec 31, 2017 | 1.80 Bn |
| Sep 30, 2017 | -718.00 Mn |
| Jun 30, 2017 | -604.50 Mn |
| Mar 31, 2017 | 1.69 Bn |
| Dec 31, 2016 | 1.77 Bn |
| Sep 30, 2016 | -526.00 Mn |
| Jun 30, 2016 | -514.00 Mn |
| Mar 31, 2016 | 1.43 Bn |
| Dec 31, 2015 | 2.02 Bn |
| Sep 30, 2015 | -1.14 Bn |
| Jun 30, 2015 | -1.76 Bn |
| Mar 31, 2015 | 295.00 Mn |
| Dec 31, 2014 | 414.50 Mn |
| Sep 30, 2014 | 2.15 Bn |
| Jun 30, 2014 | 4.96 Bn |
| Mar 31, 2014 | 4.59 Bn |
| Dec 31, 2013 | 4.03 Bn |
| Sep 30, 2013 | 3.57 Bn |
| Jun 30, 2013 | 3.26 Bn |
| Mar 31, 2013 | 1.57 Bn |